CER Groupe published a new paper in Nature Biotechnology titled Donor-complementary prime editing enables precise kilobase and library-compatible DNA insertions.
Public source
Publisher name
Public post
New paper in Nature Biotechnology: Donor-complementary prime editing enables precise kilobase and library-compatible DNA insertions. The translational value is not the h…
Company
CER Groupe
Innovation and excellence in providing services in Health and Agriculture
- Industry
- Research Services
- Company size
- 51–200 employees
About CER Groupe
CER Groupe is a CRO delivering preclinical, analytical, and bioproduction services to pharmaceutical, biotech, agrifood, medtech, and diagnostic companies developing innovations in human and veterinary health. In addition, CER Groupe operates as an accredited research center, collaborating with academic institutions and industry partners to drive scientific excellence and generate high‑impact research outcomes. Ideally located in the Walloon Region of Belgium, the organization provides studies conducted under rigorous quality standards, including GLP, ISO 9001, ISO 17025, and National Reference Laboratory (NRL) accreditations. Idéalement positionné au sein du réseau biotechnologique wallon, le CER Groupe fournit aux entreprises, institutions, universités et particuliers des services de qualité dans le domaine des sciences du vivant et de l’agriculture. Le groupe se différencie par son offre pré-clinique transversale, exécutée dans un cadre normé (ISO, GxP), permettant d’apporter une réponse complète dans l’accompagnement, l’incubation et la croissance des entreprises innovantes en Belgique et à l’étranger. Producteur de produits innovants, le groupe délivre au secteur pharmaceutique et alimentaire des anticorps polyclonaux et monoclonaux, des kits de diagnostic ainsi que leurs réactifs et du colostrum. Reconnu pour ses compétences et ses services de qualité au secteur agricole, le groupe contribue au développement économique du secteur en support à la Politique Agricole Wallonne et à la PAC Européenne.
See moreLatest activity
Latest activity from CER Groupe
5 signals
Research & Knowledge
CER Groupe published a new paper in Nature Medicine titled Limited benchmarks constrain the conclusions of a general-purpose versus clinical AI comparison.
Research & Knowledge
CER Groupe published a new paper in Nature Biotechnology titled Lessons from drug revenue life cycles: distributions across modalities and therapeutic areas.
Presence & Recognition
CER Groupe is featured in Le Soir as part of the Wallonia Institute of Food Science and Technology (WIFST) initiative.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Integrated DNA Technologies
Integrated DNA Technologies published a study by scientists highlighting the strength of their UNCOVERseq™ off-target analysis service across evaluated methods.
Research & Knowledge
Innovative Genomics Institute
Innovative Genomics Institute published a Q&A with Niren Murthy on his new way to engineer lipid nanparticles for safer genome editing in Nature Nanotechnology.
Research & Knowledge
Wellcome Sanger Institute
Wellcome Sanger Institute published a blog by Sandeep Sundara Rajan discussing CRISPR-Cas in gene function, cancer vulnerabilities, and human genetic variation.
Research & Knowledge
Center for Neuroscience and Cell Biology
Center for Neuroscience and Cell Biology researchers from CNC-UC and GeneT tested an innovative gene-editing therapeutic strategy for Machado-Joseph neurodegenerative disease using extracellular vesicles as delivery vehicles for CRISPR-Cas9.
Research & Knowledge
Synthego